Health News Archive - May 10, 2011
AMSTERDAM, May 10, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, provided today a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD). Following the submission of the Day 180 questions at the end of the first quarter to the European Medicines Agency (EMA) as part of Glybera's Market Authorisation Application (MAA), AMT continues to work diligently with the EMA and is confident that a decision on the approval of Glybera remains on track for mid-2011 as previously guided. "Our interactions with the EMA continue to be positive and we are encouraged as we hit each milestone in the path towards a regulatory decision.
WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S.
VIENNA, May 10, 2011 /PRNewswire/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs. Financial Results Year-on-year revenue growth of 19.7% driven by strong IXIAROÂ®/JESPECTÂ® sales revenues Restructuring process progressing successfully - operating loss reduced by 33.1%Higher sales and reduced spending lead to reduced net loss of EUR 11.3mCash position of EUR 87.7m at quarter-endUnchanged net loss expectation of EUR 30 40m for full year 2011 Key Financial Figures EUR in thousands 3 months ended Year ended March 31, ---------- --------- Dec.
NEW YORK, May 10, 2011 /PRNewswire/ -- New York attorney Michael Barasch is concerned about two recent reports, one from the New York City Fire Department's chief medical officer and one from Mt. Sinai Hospital.
DUBLIN and MYSTIC, Conn., May 10, 2011 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results for the quarter ended March 31, 2011 (Q1 2011).
HELSINKI, May 10, 2011 /PRNewswire/ -- - The National Association Representing the Entire Finnish Health Technology Sector Will Now Offer its Members Convenient Online Training Built Specifically for Medical Device Professionals The Finnish Health Technology Association (FiHTA) and the World Medical Device Organization (WMDO), the leading global provider of online training for medical device professionals, announced today a strategic partnership that offers Finnish medical device professionals access to WMDO's extensive catalogue of professional online training.
PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/ -- Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.
WIESBADEN, Germany, May 10, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its new FreeStyle InsuLinx Blood Glucose Monitoring System,(1,2) the first blood glucose monitoring device from Abbott that includes a mealtime (bolus) insulin calculator for calculating suggested insulin doses.
ATLANTA, May 10, 2011 /PRNewswire/ -- Surgical Information Systems ("SIS") announced today that Huntsville Memorial Hospital in Huntsville, TX, selected SIS' surgical solution to automate its perioperative department, interfacing with the hospital's current MEDITECH system to provide patient care benefits while increasing revenue and generating significant cost savings.
NEW YORK, May 10, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc.
- The act of lurking; skulking about; hiding; keeping from sight.